| Similar Articles |
|---|
 |
The Motley Fool
October 17, 2006
Brian Lawler |
Lilly Doesn't Like Sharing Profits The company is buying out ICOS Corporation, its partner in erectile-dysfunction drug Cialis. Investors, take note.   |
The Motley Fool
January 22, 2007
Brian Lawler |
Adios, ICOS The pharmaceutical gets finally consumed by Eli Lilly. The deal offered a nice premium to ICOS shareholders. At the same time, it was a good deal for Lilly. |
The Motley Fool
July 10, 2008
Brian Lawler |
Lilly Targets a Tiny Prize As drugmakers go, this acquisition's a value meal. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
August 17, 2007
Brian Lawler |
The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition. |
The Motley Fool
July 13, 2004
Brian Gorman |
The "Cialis Promise" Eli Lilly and Icos are offering a free trial of their drug Cialis for men who have never used it before and promise that participants not pleased with the results will receive a voucher for a competing product. |
Pharmaceutical Executive
February 1, 2007
Ben Bonifant et al. |
Driven to License The competition for innovative biotech products is intense, giving rise to an unprecedented diversity of partnering strategies and an equally unprecedented convergence of small-molecule drugs and biologics in company portfolios. Licensings are shaping up as the year's big deal. |
The Motley Fool
May 27, 2005
Nick Baker |
Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors? |
The Motley Fool
May 18, 2010
Brian Orelli |
What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
BusinessWeek
October 27, 2003
Michael Arndt |
Is Viagra Vulnerable? Eli Lilly's Cialis lasts for 36 hours -- and a $100 million ad blitz will spread the word. |
The Motley Fool
May 4, 2006
Stephen D. Simpson |
AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch. |
The Motley Fool
February 29, 2008
Brian Orelli |
2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed. |
BusinessWeek
February 28, 2005
David Kiley |
The Little Blue Pill -- And Pals -- Have The Blues Despite gargantuan ad budgets, sales are trailing expectations for all three erectile dysfunction contenders. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
August 16, 2011
Brian Orelli |
Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra. |
The Motley Fool
March 26, 2009
Brian Orelli |
Big Pharma's R&D Model Is Broken Bigger isn't always better. |
The Motley Fool
February 17, 2005
Karl Thiel |
Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market. |
The Motley Fool
May 1, 2007
Brian Lawler |
Cardiome Plays Dealmaker Cardiome signs a deal to develop one of Eli Lilly's drug candidates. Investors, take note. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
January 10, 2008
Brian Orelli |
Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
May 31, 2007
Ryan Fuhrmann |
Dueling Fools: Eli Lilly Bull Thanks to a couple of recent developments and a focus on research & development, the pharma giant is a worthy contender for health-care exposure in investors' portfolios. |
The Motley Fool
June 30, 2011
Brian Orelli |
Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead. |
The Motley Fool
November 21, 2008
Brian Orelli |
Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article. |
The Motley Fool
February 25, 2004
Brian Gorman |
Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry. |
The Motley Fool
April 20, 2004
Alyce Lomax |
Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds. |
The Motley Fool
October 20, 2006
Brian Lawler |
Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note. |
The Motley Fool
May 31, 2007
Brian Lawler |
Dueling Fools: Eli Lilly Bear Well-managed companies don't always make for good investments. This pharmaceutical powerhouse is a good example. |
The Motley Fool
August 23, 2004
Ben McClure |
Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest. |
The Motley Fool
October 22, 2007
Brian Orelli |
New Warnings Won't Sink ED Drug Sales Shockingly, new safety warnings won't hurt erectile dysfunction drugs. Any investor jumpiness should be looked at as a buying opportunity for smart investors. |
The Motley Fool
March 9, 2009
Brian Orelli |
Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth. |
The Motley Fool
May 27, 2005
Stephen D. Simpson |
Once More With Merck Merck has had a busy spring, but are investors any better off? |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
December 21, 2006
Brian Lawler |
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. |
Bio-IT World
December 10, 2002
Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
